**South San Francisco – January 11, 2021** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT/10:30 a.m. ET.  

**About PACT Pharma**

PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial. 

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information please visit[ www.pactpharma.com]( www.pactpharma.com). 


**Media Contact**

Sarah Sutton
Finsbury Glover Hering (FGH)
[ssutton@fgh.com](mailto:ssutton@fgh.com) 
202-337-0808

**Investor Contact**

Uneek Mehra
[umehra@pactpharma.com](mailto:umehra@pactpharma.com)


PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

Press Releases

- The round was led by Vida Ventures, a next generation life science venture firm with industry-leading experience in cell and gene therapy  
- The financing will be used to expand clinical & manufacturing development to deliver clinical data for patients with multiple solid tumor types  

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ — PACT Pharma, in pursuit of its vision to eradicate solid tumors using transformational, first-in-class fully personalized NeoTCR-T cell therapies, today announced that it has closed an oversubscribed $75 million Series C financing. This round, led by Vida Ventures, a next generation life science venture firm with industry-leading experience in the cell and gene therapy, also included current investors of PACT.  

Combined with proceeds from previous financings, PACT will use the Series C proceeds to expand the scope of its clinical plan to investigate NeoTCR-T cell products targeting multiple neoantigens for a spectrum of solid tumor types. In addition to clinical expansion, PACT will open in 2020 a next-gen GMP manufacturing facility in South San Francisco to support the end-to-end production and supply chain for the engineering of personalized neoantigen-targeted autologous T cells. Under the direction of industry veteran Tim Moore, President and Chief Technology Officer, PACT will leverage the new in-house manufacturing facility to automate manufacturing and analytic processes to reduce cycle time and manufacturing costs.  

“PACT has grown from company launch to opening its first-in-kind clinical trial in two years. Our progress has been exhilarating and the support from our existing investors has made that progress possible,” said Alex Franzusoff, PhD, Chief Executive Officer of PACT Pharma. “As we look to the next stage of our development and expansion of our clinical programs, we are excited to have interest from a new group of prominent investors who both understand the potential of NeoTCR-T cell therapy and have direct experience in the space. Vida Ventures stood out as a partner of choice, given their depth of operational experience in research, clinical development and manufacturing in cell therapy as well as their proven ability to guide companies like Kite and Allogene across key stages of development.  

As part of the Series C financing, Helen S. Kim, Managing Director at Vida Ventures, will join the Company’s Board of Directors. Ms. Kim brings over 25 years of biotechnology leadership experience and serves on the boards of Assembly Biosciences, Applied Molecular Transport, A2 Biotherapeutics and Exicure, Inc.  

“Our investment in PACT Pharma represents our goal to fund scientific advances by embracing cutting edge innovation with the potential to make a meaningful difference in the lives of patients,” said Kim. “PACT has developed a pioneering platform of personalized designer T cells with the potential to target some of the most elusive solid cancers facing society today.”  

**ABOUT PACT Pharma**  

PACT Pharma is an independent, privately funded clinical stage company, based in South San Francisco, California, developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors and is now enrolling patients in its first-in-human Phase 1 clinical studies at several key academic centers of the CIRM-funded Alpha Clinic network, in California.  

PACT Pharma’s distinguised co-founders, David Baltimore (Nobel Laureate), Antoni Ribas, Jim Heath, Terry Rosen and Juan Jaen launched the company in early 2017. The company is backed by GV (formerly Google Ventures), Canaan, Casdin Capital, Droia, Foresite Capital, Invus Opportunities, Pontifax and Wu Capital and is supported by investment from AbbVie Ventures and Taiho Ventures. PACT Pharma’s technology is designed to individually program tumor-exclusive targeting into each patient’s own immune system cells to eradicate their own cancer. The process, which is currently in Phase 1 clinical testing, involves taking a biopsy of a person’s cancer tissue to assess the tumor-exclusive mutations with predictive algorithms, then to biologically verify the optimal targets by capturing T cells from blood that already recognize the mutations. Using the T cell receptor information from the captured T cells, together with proprietary, cutting edge, (non-viral) precision genome engineering technologies, fresh patient T cells are edited in one step to craft tumor-specific neoTCR-P1 cells. These private designer T cells have been shown to immediately kill mutation-expressing tumors in pre-clinical studies, and to create a deep reservoir of ‘ready-to-go’ neoTCR-P1 cells with the potential for long term persistence to prevent future cancer recurrence. These developments offer PACT exceptional prospects to leverage the potential of ideal tumor targets and biologically verified neoTCRs into clinical development of neoTCR-T adoptive cell therapies.  

**CONTACT:** William Nevius, wnevius(at)canaan.com

PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer

PACT is a company pushing the frontiers of science, technology and medicine. We are creating T cell therapies to alter the course of cancer and meaningfully impact the lives of patients who urgently need breakthrough therapies. We are building a team of driven, talented and passionate individuals committed to bringing these novel personalized therapies to people living with cancer.

Join Us

PACT is a clinical stage immuno-oncology company dedicated to engineering T cell therapies by seeking to harness the inherent biology and curative potential of each patient's immune system to treat their cancer and advance the field of immune-driven medicines.

Who We Are

PACT Pharma is an exciting, well-funded clinical-stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient’s individual tumor and engineering T cells to kill that specific tumor. If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team.  We are a diverse work family with a dynamic and earnest culture. We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer!We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.We are currently recruiting for a Research Associate II - Protein Sciences who will report to the head of Protein Science Laboratory Operations and continue advancing PACT’s cutting-edge engineered cell product. This will be a unique opportunity to see your ideas rapidly translate into the clinic and impact patient lives. What you will do: <ul><li style="line-height: normal;">Support the Protein Production pipeline with high-throughput DNA Prep, cloning, protein expression and purification.</li><li style="line-height: normal;">Expression and purification of recombinant proteins in mammalian host system</li><li style="line-height: normal;">Coordinate activities with functional groups and project teams</li><li style="line-height: normal;">Update electronic lab notebook entries, inventory and documentation</li></ul> Qualifications:<ul><li style="line-height: normal;">Bachelor’s degree in Protein Biochemistry, Molecular Biology or related discipline with 2 years of related or lab experience.</li><li style="line-height: normal;">Prior experience with DNA Prep in e.coli, mammalian cell culture and/or recombinant protein expression.</li><li style="line-height: normal;">Prior experience with high-throughput cloning and protein purification is plus</li><li style="line-height: normal;">Acute attention to details, well-organized, diligent with documentation.</li><li style="line-height: normal;">Experience with liquid handling platforms such as Hamilton, Tecan, etc. desired.</li><li style="line-height: normal;">Highly goal-driven and displays the ability to handle delicate experiments in a timely manner.</li><li style="line-height: normal;">Demonstrated experience operating within a defined Quality Management System is a plus.</li><li style="line-height: normal;">Able to operate in a collaborative environment and communicate clearly and concisely, both verbally and in the form of written reports.</li></ul>PACT Pharma is proud to be an equal opportunity employer and strives to build a diverse and inclusive team. We do not discriminate based on race, color, national origin, religion, gender, sexual orientation, age, marital status, veteran status, or disability status.

Corporate (South San Francisco)

Research Associate II

PACT Pharma is an exciting, well-funded clinical-stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient’s individual tumor and engineering T cells to kill that specific tumor.If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team.  We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer!We are in the San Francisco Bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.We are currently recruiting for Process Development Scientist reporting to the Sr. Director of Manufacturing Development. This position will be based in South San Francisco.The candidate will lead experimental research projects in the process development team developing PACT Pharma’s cell manufacturing process.  Furthermore, they will interact closely with Scientists and Research Associates of PACT’s manufacturing team for technology transfer.  They will be actively performing experiments and should be highly proficient in state-of-the-art techniques for primary cell culture, cell analysis, and related instrumentation. The candidate should enjoy operating in an exceptionally dynamic and cooperative environment.Responsibilities:<ul><li style="line-height: normal;">Design, perform and analyze experimental process development studies to support the development of the next-generation cell therapy manufacturing process</li><li style="line-height: normal;">Interact closely with associated departments to support technology transfer to manufacturing</li><li style="line-height: normal;">Support of regulatory submissions by authoring/reviewing study reports or CMC sections</li><li style="line-height: normal;">Maintain rigor and quality of execution and documentation</li><li style="line-height: normal;">Manage multiple process development projects cross-functionally and provide routine progress updates on timelines and deliverables</li><li style="line-height: normal;">Give presentations within the department and to senior management with minimal supervision</li><li style="line-height: normal;">May be expected to provide assistance to other research associate level team members</li></ul>Qualifications:  <ul><li style="line-height: normal;">Ph.D. with experience in T cell biology (or related field) with 2+ years of experience or MS with 8+ years of experience.</li><li style="line-height: normal;">Prior cell therapy manufacturing and/or process development experience desired</li><li style="line-height: normal;">Familiarity with cGMP requirements is a plus</li><li style="line-height: normal;">The candidate should be highly goal-driven and have demonstrated the ability to focus on time-sensitive objectives</li><li style="line-height: normal;">Excellent organizational skills and should be able to communicate clearly and concisely, both verbally and in the form of written reports</li><li style="line-height: normal;">Proven ability to work independently, as well as to collaborate with peers and work effectively in a fast-paced team-oriented environment</li></ul>PACT Pharma is proud to be an equal opportunity employer and strives to build a diverse and inclusive team. We do not discriminate on the basis of race, color, national origin, religion, gender, sexual orientation, age, marital status, veteran status, or disability status.

Process Development Scientist

“I joined PACT to work with our impressive management team and innovative technologies to improve cancer therapies. It is the people that make this company exceptional and the mission to cure cancer that motivates me.”

thumbnail_Rebecca.jpg

Rebecca.jpg

Director

"I joined PACT because of the science and the people!  PACT is a special place where people work hard because they are passionate about the science, committed to patients, value teamwork and push the boundaries to never accept the status quo. For those who thrive in a fast paced and innovative environment, PACT provides a rewarding opportunity to tackle challenging projects in a collaborative way."

thumbnail_Susan.png

Susan.png

Vice President

“I joined PACT Pharma because I was energized by the people and the purpose of the organization and have been continuously impressed by the drive and ambition of the whole team to overcome any challenges. Being encouraged to be authentic with one another, and in all of our work, has really built a strong, unified team. This has been a unique and very rewarding experience for me.”

thumbnail_Brian_Birdi.jpg

Brian_Birdi.jpg

Associate Director

“When I first interviewed at PACT, I remember being impressed by the collaborative and open nature of research within the company. It left quite the impression with me and ultimately guided me towards choosing a career at PACT. Since joining, I am continually grateful for the level of openness and collaboration between teams and departments that is crucial for pioneering scientific work."


Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

Who We Are

Mission & Vision

Our
Platform

Our
Programs

PACT Voices

Director

Technical Operations

Vice President

Program Management

Associate Director

Automation

Scientist

Tumor Immunology

Join Us

Research Associate II

Process Development Scientist

Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

Who We Are

Mission & Vision

OurPlatform

OurPrograms

PACT Voices

Director

Technical Operations

Vice President

Program Management

Associate Director

Automation

Scientist

Tumor Immunology

Join Us

Research Associate II

Process Development Scientist

Our
Platform

Our
Programs